<DOC>
	<DOC>NCT01099306</DOC>
	<brief_summary>This study devised an experimental focused pharmaceutical care program, allowed a clinical pharmacist to work in a physician office to assess and manage patients' metabolic syndrome status and its individual components. This study described the clinical benefits of physician- clinical pharmacist interaction in achieving improved glycemic control, lipid and blood pressure measurements, involving medication, diet, physical activity and patient heath care counseling.</brief_summary>
	<brief_title>Pharmacist - Physician Collaborative Approach to the Management of Metabolic Syndrome</brief_title>
	<detailed_description>A single blinded prospective randomized controlled trial conducted in family medicine outpatients clinics in Jordan. The study enrolled 199 patients met the National Cholesterol Education Program Adult Treatment Panel III (NCEP/ATPIII) criteria for the diagnosis of MS upon the time of enrollment. Patients were randomized into: 110 participants into the intervention arm (pharmacist-physician collaborative approach) and 89 into the control arm (physician only team). Only patients in the intervention arm were provided pharmacist recommendations and pharmaceutical care counseling.</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<criteria>Meeting at least 3 of the 5 criteria for the National Cholesterol Education Program Adult Treatment Panel III (NCEP/ATPIII) for the diagnosis of Metabolic syndrome upon the time of enrollment. : 1. Abdominal circumference &gt;102 cm in males or &gt;88 cm in females. 2. HDL cholesterol &lt; 40 mg/dl for males or &lt; 50 mg/dl for females. 3. Triglycerides ≥ 150 mg/dl. 4. Blood pressure ≥ 130/85 mmHg or receiving hypertension treatment. 5. Baseline glycemia ≥ 110 mg/dl. 1. Patients with hypertensive urgency or emergency with BP more than (180/110). 2. Patients with recent stroke or myocardial infraction (within past 6 months). 3. Patients with Class III or IV Chronic heart Failure (CHF). 4. Patients with Unstable angina. 5. Patients with Serious renal or hepatic disease. 6. Pregnant patients. 7. Patients with Dementia or cognitive impairment. 8. If the patient is unable to provide informed written consent.</criteria>
	<gender>All</gender>
	<minimum_age>32 Years</minimum_age>
	<maximum_age>88 Years</maximum_age>
	<verification_date>March 2009</verification_date>
</DOC>